Andersen et al. showed that more than 60% of malignant cutaneous melanomas (compared to ~20% of nevi) express LRP2, and that LRP2 knockdown decreases melanoma cell proliferation and survival, underscoring a growth-supporting role in this context [50]. Here, LRP2 is linked to cutaneous melanoma.